{
    "clinical_study": {
        "@rank": "127755", 
        "arm_group": [
            {
                "arm_group_label": "Ambrisentan", 
                "arm_group_type": "Experimental", 
                "description": "Subjects in this arm will receive ambrisentan 5 mg tablet once daily during the treatment period."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects in this arm will receive ambrisentan-matching placebo tablet once daily during the treatment period."
            }
        ], 
        "brief_summary": {
            "textblock": "It is hypothesised that ambrisentan may provide benefit to subjects with inoperable chronic\n      thromboembolic pulmonary hypertension (CTEPH), where currently no proven or licensed\n      treatment options exist. This Phase III, randomized, double-blind placebo controlled\n      parallel group, 16 week study will compare the safety and efficacy of ambrisentan 5\n      milligrams (mg) versus placebo in subjects with inoperable CTEPH. The study will enrol 160\n      subjects, to assure at least 72 evaluable subjects per treatment arm, based on 10% drop-out\n      rate."
        }, 
        "brief_title": "Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension.", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": [
                "Hypertension", 
                "Hypertension, Pulmonary"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed written informed consent prior to beginning study-related procedures.\n\n          -  Subject must be between 18-75 years of age, inclusive, at the Screening Visit.\n\n          -  Subjects must have a diagnosis of Chronic Thromboembolic Pulmonary Hypertension\n             (CTEPH) at an expert centre with a positive Ventilation-perfusion lung scan (V/Q) and\n             computed axial tomography (CT) angiogram and a pulmonary angiogram if available\n             within 3 months prior to screening.\n\n          -  Subject must meet all of the following haemodynamic criteria by means of a right\n             heart catheterization (RHC) within 4 weeks prior to screening:  Mean pulmonary artery\n             pressure (mPAP) of >25 millimeters of mercury (mmHg), Pulmonary vascular resistance\n             (PVR) >400 dynes.sec/centimetre (cm)^5, Pulmonary capillary wedge pressure (PCWP) or\n             Left ventricle end diastolic pressure (LVEDP) of <15 mmHg.\n\n          -  Subjects must have previously been judged inoperable due to the obstruction being\n             surgically inaccessible (i.e. distal disease) by an expert multidisciplinary team\n             which must include at least one cardiology or respiratory consultant, and one\n             consultant PEA surgeon. For countries with CTEPH expert centers [including at least a\n             surgeon with sound experience performing Pulmonary Endarterectomy (PEAs)] the expert\n             team will be the local expert centre. For countries without a CTEPH surgical expert\n             center a central adjudication committee will assess the operability of the subjects\n             during the screening period.\n\n          -  Subject must walk a distance of >150 Meters (m) and < 475 m at the screening visit.\n\n          -  Subject must have a current diagnosis of being in WHO Functional Class II or III.\n\n          -  Subject, with or without supplemental oxygen, must have a resting arterial oxygen\n             saturation (SaO2) > 92% as measured by pulse oximetry at the Screening Visit.\n\n          -  Subjects must have received anticoagulation for a minimum of 3 months prior to\n             Screening\n\n          -  Female subject of childbearing potential must agree to use 2 reliable methods of\n             contraception from the Screening Visit until study completion and for at least 30\n             days following the last dose of Investigational Product\n\n          -  Subject must agree not to participate in a clinical study involving another\n             investigational drug or device throughout this study.\n\n          -  Subject must be competent to understand the information given in the Institutional\n             Review Board (IRB) or Independent Ethics Committee (IEC) approved informed consent\n             form (ICF) and must sign the form prior to the initiation of any study procedures.\n\n        Exclusion Criteria:\n\n          -  Subject received previous Pulmonary arterial hypertension (PAH) therapy\n             (Phosphodiesterase type 5 [PDE5i], Endothelin receptor antagonist [ERA], chronic\n             prostanoid use)\n\n          -  Subject has previously discontinued other ERA in either another clinical study or\n             commercial product for safety or tolerability reasons other than for liver function\n             abnormalities.\n\n          -  Subject has a known hypersensitivity to the Investigational Products, the\n             metabolites, or formulation excipients\n\n          -  Subject has previously undergone a pulmonary endartorectamy\n\n          -  Subject receiving intravenous inotropes within 2 weeks prior to the Screening Visit\n             (e.g. dopamine, dobutamine)\n\n          -  Subjects receiving Calcium Channel Blockers or 5-hydroxy-3-methylglutaryl-coenzyme A\n             5-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (i.e., statins)\n             on an unstable dose 4 weeks prior to the Screening Visit (to be eligible subjects\n             must not have changed their dose <4 weeks prior to the screening visit)\n\n          -  Subject has not enrolled in an exercise training program for cardiopulmonary\n             rehabilitation within 12 weeks prior to the Screening Visit and must agree not to\n             enroll in an exercise training program for pulmonary rehabilitation during the\n             Screening Period and the first 16 weeks of the study. Subjects enrolled in an\n             exercise program for pulmonary rehabilitation 12 weeks prior to screening may enter\n             the study if they agree to maintain their current level of rehabilitation for the\n             first 16 weeks of the study.\n\n          -  Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) > 3x Upper\n             limit of normal (ULN)\n\n          -  Bilirubin > 1.5xULN (>35% direct bilirubin)\n\n          -  Subject has severe renal impairment [estimated creatinine clearance <30\n             millilitre/minute (mL/min)] at the Screening Visit\n\n          -  Subject has moderate - severe hepatic impairment (Child-Pugh class B-C with or\n             without cirrhosis) at the Screening Visit\n\n          -  Subject has clinically significant anaemia: Hemoglobin (Hb) < 10 grams/decilitre\n             (g/dL)\n\n          -  Subjects with bleeding disorders or significant active peptic ulceration in the\n             opinion of the investigator\n\n          -  Subject has uncontrolled hypertension (>180/110 mmHg) at screening\n\n          -  Subject has severe hypotension (<90/50 mmHg) at screening\n\n          -  Subject has had an acute myocardial infarction within the last 90 days prior to\n             screening\n\n          -  Subject has, in the opinion of the investigator, clinically significant aortic or\n             mitral valve disease; pericardial constriction; restrictive or congestive\n             cardiomyopathy; life-threatening cardiac arrhythmias; significant left ventricular\n             dysfunction (ejection fraction <50% of normal); left ventricular outflow obstruction;\n             symptomatic coronary artery disease; autonomic hypotension; fluid depletion.\n\n          -  Subject with significant pulmonary disease Forced expiratory volume in 1 second\n             (FEV1) <70% of predicted): Chronic obstructive pulmonary disease (COPD), Emphysema,\n             evidence of fibrotic lung disease on imaging\n\n          -  Subject has clinically significant fluid retention in the opinion of the investigator\n\n          -  Subject with significant obesity [Body mass index (BMI) \u226535], cardiovascular,\n             musculoskeletal or any other condition that in the opinion of the investigator may\n             involve an impairment of exercise capacity or the performance of the 6MWD test (e.g.\n             previous history of hip/knee surgery, lower limb ulcers associated with autoimmune\n             diseases)\n\n          -  Subject with cardiovascular, liver, renal, haematologic, gastrointestinal,\n             immunologic, endocrine, metabolic, or central nervous system disease that, in the\n             opinion of the Investigator, may adversely affect the safety of the subject and/or\n             efficacy of the investigational product or severely limit the lifespan of the subject\n             other than the condition being studied\n\n          -  Subjects with a prior malignancy whose cancer is expected to require additional\n             active treatment in the next 2 years and whose prior malignancy would prevent them\n             from fully participating in the study\n\n          -  Female subject who is pregnant or breastfeeding\n\n          -  Subject has demonstrated noncompliance with previous medical regimens\n\n          -  Subject has a recent (within 1 year) history of abusing alcohol or illicit drugs\n\n          -  Subject has participated in a clinical study involving another investigational drug\n             or device within 4 weeks before the Screening Visit."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01884675", 
            "org_study_id": "115811"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ambrisentan", 
                "description": "White, film-coated, immediate-release tablets, containing 5 mg ambrisentan for single dose oral.", 
                "intervention_name": "Ambrisentan 5 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "White, film-coated, ambrisentan-matching placebo tablet for single oral dose", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Endothelin Receptor Antagonist", 
            "Inoperable Chronic Thromboembolic Pulmonary Hypertension"
        ], 
        "lastchanged_date": "May 29, 2014", 
        "location": [
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Graz", 
                        "country": "Austria", 
                        "zip": "A-8036"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Innsbruck", 
                        "country": "Austria", 
                        "zip": "A-6020"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Vienna", 
                        "country": "Austria", 
                        "zip": "1090"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Edmonton", 
                        "country": "Canada", 
                        "state": "Alberta", 
                        "zip": "T6G 2B7"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "N6A 5W9"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China", 
                        "state": "Hubei", 
                        "zip": "430022"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100037"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100038"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200433"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Praha 2", 
                        "country": "Czech Republic", 
                        "zip": "128 08"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Germany", 
                        "state": "Baden-Wuerttemberg", 
                        "zip": "69126"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Regensburg", 
                        "country": "Germany", 
                        "state": "Bayern", 
                        "zip": "93053"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Wuerzburg", 
                        "country": "Germany", 
                        "state": "Bayern", 
                        "zip": "97076"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Hannover", 
                        "country": "Germany", 
                        "state": "Niedersachsen", 
                        "zip": "30625"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Homburg", 
                        "country": "Germany", 
                        "state": "Saarland", 
                        "zip": "66421"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany", 
                        "state": "Sachsen", 
                        "zip": "01307"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany", 
                        "state": "Sachsen", 
                        "zip": "04103"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Fukuoka", 
                        "country": "Japan", 
                        "zip": "812-8582"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Hokkaido", 
                        "country": "Japan", 
                        "zip": "060-8648"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Hyogo", 
                        "country": "Japan", 
                        "zip": "650-0017"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Miyagi", 
                        "country": "Japan", 
                        "zip": "980-8574"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Tochigi", 
                        "country": "Japan", 
                        "zip": "329-0498"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan", 
                        "zip": "181-8611"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan", 
                        "zip": "113-8655"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "120-752"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "110-744"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "135-710"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Monterrey NL", 
                        "country": "Mexico", 
                        "state": "Nuevo Le\u00f3n", 
                        "zip": "64718"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1081 HV"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Kemerovo", 
                        "country": "Russian Federation", 
                        "zip": "650002"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Tomsk", 
                        "country": "Russian Federation", 
                        "zip": "634012"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08036"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Majadahonda (Madrid)", 
                        "country": "Spain", 
                        "zip": "28222"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain", 
                        "zip": "41013"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Cambridge", 
                        "country": "United Kingdom", 
                        "zip": "CB23 3RE"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Clydebank", 
                        "country": "United Kingdom", 
                        "zip": "G81 4DY"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "NW3 2QH"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Canada", 
                "China", 
                "Czech Republic", 
                "Germany", 
                "Japan", 
                "Korea, Republic of", 
                "Mexico", 
                "Netherlands", 
                "Russian Federation", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Multicentre, Double-Blind, Placebo-Controlled Study Of Ambrisentan In Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH).", 
        "overall_contact": {
            "email": "GSKClinicalSupportHD@gsk.com", 
            "last_name": "US GSK Clinical Trials Call Center", 
            "phone": "877-379-3718"
        }, 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Russia: Federal Service for Drug Control of the Russian Federation (FSKN)", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Austria: Agency for Health and Food Safety", 
                "Italy: Italian Medicines Agency", 
                "Brazil: National Health Surveillance Agency", 
                "Mexico: Federal Comission For The Protection Against Sanitary Risks (COFEPRIS)", 
                "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica", 
                "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "South Korea: Korea Food and Drug Administration (KFDA)", 
                "Czech Republic: State Institute for Drug Control", 
                "Canada: Health Canada", 
                "France: National Agency for the Safety of Medicine and Health Products", 
                "Netherlands: Medicines Evaluation Board (MEB)", 
                "Japan: Pharmaceuticals and Medical Devices Agency", 
                "Spain: Spanish Agency for Medicines and Health Products", 
                "China: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change from baseline in 6MWD (walk distance during 6 minute) will be measured at Screening, Baseline,  Week 4, Week 8, Week 12 and Week 16", 
            "measure": "Change from baseline in 6-minute walk distance (6MWD)", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Week 16"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01884675"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Pulmonary vascular resistance is defined as the resistance to flow that must be overcome to push blood through the circulatory system by the vasculature of the lungs.", 
                "measure": "Change from baseline in pulmonary vascular resistance (PVR)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 16"
            }, 
            {
                "description": "World Health Organization Functional Class will be assessed at each clinic visit.", 
                "measure": "Change from baseline in Functional Class (FC)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 16"
            }, 
            {
                "description": "Borg CR10 Scale will be scored immediately following exercise", 
                "measure": "Change from baseline in Borg CR10 Scale (BCR10S)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 16"
            }, 
            {
                "description": "Clinical worsening of CTEPH, as defined by the time from randomization to the first occurrence of death, lung transplantation, hospitalization for CTEPH, atrial septostomy, addition of parenteral prostanoids, or study withdrawal due to early escape", 
                "measure": "Change from baseline in Clinical worsening of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 16"
            }, 
            {
                "description": "Other haemodynamics will include: Right atrial pressure millimeters mercury (mm Hg), pulmonary artery pressure (mm Hg) and cardiac index liter/minutes/meter square (L/min/m^2)", 
                "measure": "Change from baseline in other haemodynamics", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 16"
            }, 
            {
                "measure": "Change from baseline in N-terminal pro-B-type natriuretic peptide( NT-proBNP)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 16"
            }, 
            {
                "description": "Quality of Life as measured by the Short Form 36 Health Survey", 
                "measure": "Change from baseline in Quality of Life as measured by SF-36 Health Survey (SF-36)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 16"
            }, 
            {
                "measure": "Incidence of adverse events and serious adverse events", 
                "safety_issue": "No", 
                "time_frame": "Up to 16 Weeks"
            }, 
            {
                "measure": "Change from baseline in haemoglobin or haematocrit levels", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 16"
            }, 
            {
                "measure": "Safety as assessed by liver testing abnormalities", 
                "safety_issue": "No", 
                "time_frame": "Up to 16 Weeks"
            }, 
            {
                "description": "Supine blood pressure and heart rate", 
                "measure": "Safety as assessed by vital signs measurements", 
                "safety_issue": "No", 
                "time_frame": "Up to 16 Weeks"
            }, 
            {
                "description": "Clinical chemistry, haematology, testicular function (males only)", 
                "measure": "Safety as assessed by laboratory test measurements", 
                "safety_issue": "No", 
                "time_frame": "Up to 16 Weeks"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}